Virulizin

Area of Science:

• Immunology and Oncology
• Pharmacology and Drug Development

Background:

• Virulizin is a biological response modifier derived from bovine reticuloendothelial tissue.
• It functions by activating macrophages and is under development for various cancers.

Purpose of the Study:

• To evaluate Virulizin's efficacy and safety in treating advanced pancreatic cancer.
• To assess Virulizin as a first- and second-line treatment in combination with standard chemotherapies.

Main Methods:

• Phase III clinical trial comparing Virulizin + gemcitabine versus gemcitabine alone for first-line therapy.
• Second-line therapy assessed Virulizin + fluorouracil versus fluorouracil alone in patients resistant to gemcitabine.

Main Results:

• Meta-analysis of Phase I/II studies indicated Virulizin improved survival and quality of life in pancreatic cancer patients.
• Orphan drug and fast track designations were granted by the US FDA for pancreatic cancer treatment.

Conclusions:

• Virulizin demonstrates potential as a therapeutic agent for advanced pancreatic cancer.
• Ongoing studies and preclinical research suggest broader applications in other malignancies.